ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,618.26
      -0.29%
      US Tech 100
      18,927.60
      -0.06%
      Dow Jones
      41,503.10
      -0.25%
      Brent Oil
      72.745
      0.50%
      Bitcoin
      61,943.61
      0.44%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. ZIOPHARM Oncology Inc (ZIOP) Quote

      ZIOPHARM Oncology Inc

      ZIOPHARM Oncology Inc (ZIOP)

      NASDAQ
      0.8657
      0.00
      (0.00%)
      Closed September 18 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      0.8657
      Bid
      0.865
      Ask
      0.97
      Volume
      -
      0.00 Day's Range 0.00
      0.00 52 Week Range 0.00
      Market Cap
      208.311M
      Previous Close
      0.8657
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      -
      Shares Outstanding
      240,627,000
      Dividend Yield
      -
      PE Ratio
      -21.16
      Earnings Per Share (EPS)
      -0.15
      Revenue
      303k
      Net Profit
      -35.14M

      About ZIOPHARM Oncology Inc

      ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner I... ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Spec Outpatient Facility,nec
      Website
      www.ziopharm.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      2016

      Ask ADVFN Intelligence (AI)

      ZIOP Latest News

      More News

      FeaturedElement79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership

      12 hours ago

      Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

      Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2...

      January 26 2022
      GlobeNewswire Inc.

      Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

      HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential...

      November 09 2021
      GlobeNewswire Inc.

      Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

      HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021...

      November 08 2021
      GlobeNewswire Inc.

      Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

      HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended...

      November 01 2021
      GlobeNewswire Inc.

      Ziopharm Oncology to Participate in September Investor Conferences

      BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of...

      September 01 2021
      GlobeNewswire Inc.

      Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

      Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value...

      August 30 2021
      GlobeNewswire Inc.

      Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates

      Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company’s manufacturing facility and presentation of favorable preclinical data Closed venture debt...

      August 09 2021
      GlobeNewswire Inc.

      Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021

      BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to...

      July 26 2021
      GlobeNewswire Inc.

      Ziopharm Oncology to Participate in Upcoming Conferences

      BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor...

      May 24 2021
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000CS
      40000000CS
      120000000CS
      260000000CS
      520000000CS
      1560000000CS
      2600000000CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      OMEXOdyssey Marine Exploration Inc
      $ 1.39
      (180.07%)
      		324.51M
      PRTGPortage Biotech Inc
      $ 9.91
      (118.76%)
      		49.9M
      APLTApplied Therapeutics Inc
      $ 7.85
      (68.82%)
      		49.49M
      XCHXCHG Ltd
      $ 18.39
      (65.68%)
      		1.26M
      WBUYWeBuy Global Ltd
      $ 0.18675
      (60.99%)
      		228.66M
      GLMDGalmed Pharmaceuticals Ltd
      $ 6.8501
      (-54.64%)
      		5.79M
      KAKineta Inc
      $ 0.5691
      (-31.35%)
      		530.66k
      DTSSDatasea Inc
      $ 2.07
      (-29.59%)
      		1.28M
      CBUSCibus Inc
      $ 3.595
      (-28.95%)
      		2.25M
      BFIBurgerFi International Inc
      $ 0.1705
      (-26.98%)
      		16.23M
      OMEXOdyssey Marine Exploration Inc
      $ 1.39
      (180.07%)
      		328.97M
      NVDANVIDIA Corporation
      $ 113.37
      (-1.92%)
      		310.35M
      WBUYWeBuy Global Ltd
      $ 0.1867
      (60.95%)
      		248.03M
      SQQQProShares UltraPro Short QQQ
      $ 8.40
      (1.45%)
      		200.73M
      LUNRIntuitive Machines Inc
      $ 7.4512
      (37.99%)
      		141.86M

      Discussion

      View Full Feed
      havnagoodtime havnagoodtime 40 seconds ago
      "WE" got a contract...lol. Dennis couldn't sell air conditioners in 95 degree heat. One of his new Optilan subs probably got the contract for whatever it is they produce. The subs he picked up in India and Turkey -- he picked up on the cheap from his Optilan UK bankruptcy liquidation. If Dennis's Op
      DPLS
      Smilin_B Smilin_B 2 minutes ago

      Exactly....too bad there's no real discussion about this and zero institutional interest
      IMPP
      janice shell janice shell 2 minutes ago
      I'm sometimes annoyed enough to watch for it. And sometimes it never comes, or the disease is described so vaguely that once it's over, you don't have a clue what the disease may be.
      nickeli54 nickeli54 3 minutes ago
      Churning nicely
      AAGC
      James56 James56 3 minutes ago
      Yep.
      RITE
      nickeli54 nickeli54 3 minutes ago
      All coming and nothing to stop it now! It’s the best play in the OTC hands down.
      AAGC
      Jason2931 Jason2931 3 minutes ago
      What’s this I hear of LB teaming up with Durango Cannabis for a joint venture? I don’t see anything about it and they didn’t mention it on X so asking here.
      INQD
      nickeli54 nickeli54 3 minutes ago
      It’s got all the ingredients for sure. This is a patience play that will reward all that get in trips and low dubs. As long as you can endure the big swings that will come as it starts to run up to a penny.
      AAGC
      Arnold25764 Arnold25764 3 minutes ago
      It may continue lower. You still going to hold?
      DBGI
      CanItBThisEZ2Make CanItBThisEZ2Make 4 minutes ago
      https://investorshub.advfn.com/uimage/uploads/2024/9/18/ioxlmFB_IMG_1726694444260.jpg

      GO TRITOM
      GO VOS
      GO SRMX(TCCI)$
      SRMX
      fuagf fuagf 5 minutes ago
      Good movie. And good to see DeVito and Nicholson still alive.
      joyceschoice joyceschoice 5 minutes ago
      Yes the pink sheets and maybe the expert market since they haven't filed their financials yet.

      https://www.youtube.com/watch?v=ClU3fctbGls

      Will be interesting to follow the outcome.
      EGIOQ
      NASDAQ2020 NASDAQ2020 5 minutes ago
      https://www.cbsnews.com/news/fda-approves-generic-oxycontin/

      From 2003

      Is your head spinning around yet, lol
      ELTP
      blackhawks blackhawks 6 minutes ago
      They HAVE to, by law, communicate the indication(s). Usually it's spoken, but easy to miss. It also appears on the screen like the brief 'with diet and exercise' pro forma for Jardiance. But unless it's about your malady who pays that much attention?
      ChannelTrader ChannelTrader 6 minutes ago
      Gutfeld live ... https://lakestreams.com/fox-news/
      familyof5 familyof5 6 minutes ago
      Just having a little fun poking the bear lol. All in good taste lol. We all know some of these close’s should have been greener!.....
      RDGL
      Cake Eater Cake Eater 8 minutes ago
      Accord Healthcare filed an Abbreviated New Drug Application (ANDA) No. 213564 for approval to market a generic version of OxyContin. The exact date of filing is not specified, but it occurred sometime prior to October 2020, as evidenced by the lawsuit filed by Purdue Pharma against Accord Healthcare
      ELTP
      Viking61 Viking61 8 minutes ago
      More and more will be failing with the amount of illegals in the US. Look at Arizona.
      FNMA
      Reluctant Observer Reluctant Observer 9 minutes ago
      Gillian’s XRP?
      XRPUSD
      bigtalan bigtalan 9 minutes ago
      Yes the increase is on one of my accounts that holds 11,640,000 share so this increase shot it up. My avg is.00114 , just wish I was able to buy when it went into EM but I am fine with the 15m I currently have . GLTA
      Symbol Change $ Change % Qty # Price Paid $ Day's Gain $ Total Gain $ Total
      RSPI
      kBletsgo30 kBletsgo30 10 minutes ago
      I wish I had that money damn it!
      RSPI
      fuagf fuagf 10 minutes ago
      Trump's 'loving' phrases: Gonna work with farmers, applause. Gonna get energy down 50%, applause. The border people coming in are destroying us, no applause because no the audience is asking the questions .. https://www.foxnews.com/video/6362046188112 .

      Multi lies misinformation
      3331 3331 11 minutes ago
      BIEL (Bioelectronics):
      5 FDA clearances.
      https://recoveryrx.carrd.co/
      Standard of Care potential for every adult and pet on the planet.
      bigtalan bigtalan 11 minutes ago
      Yes the increase is on one of my accounts that holds 11,640,000 share so this increase shot it up. My avg is.00114 , just which I was able to buy when it went into EM but I am fine with the 15m I currently have . GLTA
      RSPI

      Your Recent History

      NASDAQ
      ZIOP
      ZIOPHARM Oncology
      Delayed Upgrade Clock